DOPA Decarboxylase

A new study identifies DOPA decarboxylase in spinal fluid as a precise biomarker for Parkinson’s and Lewy body dementia. This discovery offers a reliable way to distinguish these diseases from Alzheimer's, reducing the risk of harmful misdiagnosis.